Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers
- Abbreviated Name
- William Rom Supplement 2012
- Lead Investigator
- Rom, William — New York University School of Medicine
- Coordinating Investigator
- No coordinating investigator
- Involved Investigators
Abstact
Aims
Specific Aim 1. Develop a novel biomarker panel based on our auto-antibody publication and our development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Specific Aim 2. Test the autoantibody panels on CT-scan screen-detected lung cancers including both indolent and aggressive cancers, and validate with thoracic surgery lung cancer cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.” Each lung cancer case will be matched to a control with normal CT scans by smoking, gender, and age.
Analytic Method
development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Each sample will be assessed in triplicates, and the average value at 490 nm will be used for data analysis. During the 02 year we will be focusing our efforts at completing the assays and data analysis.
Biomarkers
- CCL18
- CCNA1
- CCNB1
- CCND1
- CDK12
- CEACAM5
- Endostatin
- HAPLN1
- HSP90AA1
- MYC
- pleiotrophin
- PRKCI
- SLPI
- Survivin
- TFPI
- TIMP1
- TNFSF8
Data Collections
- No data available at this time for this protocol
Team Project
- Protocol ID
- 361
- Field of Research
- Glycomics
- Collaborative Group
- Lung and Upper Aerodigestive Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of bronchus and lung